News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Clinical - Phase III
Saga Continues for Sarepta (SRPT) as FDA Head Calls for Retraction of 'Misleading' 2013 Study 9/23/2016
This Biotech Has the Upper Hand Over Allergan (AGN) and Gilead (GILD) in the Heated Nash Battle 9/23/2016
H. Lundbeck A/S (LUN.CO)'s Phase III Data Crushes Hope for Alzheimer’s Once Again 9/23/2016
Findings From AcelRx (ACRX)' Phase 3 SAP301 Study Of ARX-04 In Abdominoplasty Patients To Be Presented At Plastic Surgery Meeting 9/23/2016
AbbVie (ABBV) Presents Data On Eight-Week Treatment Of VIEKIRAX (Ombitasvir/Paritaprevir/Ritonavir Tablets) + EXVIERA (Dasabuvir Tablets) In Patients With Genotype 1b Chronic Hepatitis C 9/23/2016
Enanta Pharmaceuticals, Inc. Announces Data On Eight-Week Treatment Of AbbVie (ABBV)’s VIEKIRAX (Ombitasvir/Paritaprevir/Ritonavir Tablets) + EXVIERA (Dasabuvir Tablets) In Patients With Genotype 1b Chronic Hepatitis C 9/23/2016
Armed With Fresh Phase III Data, Novartis AG (NVS) Eyes First-Line Use for Lung Cancer Drug Zykadia 9/23/2016
Gilead (GILD) Terminates Phase II/III Study of Ulcerative Colitis Drug 9/22/2016
Pharma Bro Warned You: Mast Therapeutics (MSTX) Craters After Drug Flunks Phase III Test, Job Cuts Expected 9/22/2016
Teva (TEVA) Announces Positive Top-Line Data From Second Phase III Study Of SD-809 In Tardive Dyskinesia (TD) 9/22/2016
Aradigm Corporation (ARDM) Announces Last Patient Dosing Visit In ORBIT-3 And ORBIT-4 Phase 3 Studies Of Pulmaquin In Non-Cystic Fibrosis Bronchiectasis Patients 9/22/2016
PharmaMar Submits MAA To EMA For Aplidin For The Treatment Of Multiple Myeloma 9/22/2016
Sanaria Inc. PfSPZ Vaccine Against Malaria Receives D&A Pharma Fast Track Designation 9/22/2016
CureMark Release: Blüm Study - A Phase 3 Clinical Trial For Children With Autism 9/22/2016
Antares Pharma (ATRS) Announces Completion Of The Quickshot Testosterone Clinical Program 9/22/2016
Peregrine (PPHM) Provides Update On Oral Presentation Of Top-Line Data From Phase III SUNRISE Trial Of Bavituximab At European Society For Medical Oncology (ESMO) 2016 Congress 9/21/2016
Adamas Pharma (ADMS) Announces Results Of EASE LID 3, A Pivotal Trial Of ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson’s Disease Patients At The 4th World Parkinson Congress 9/21/2016
Aimmune (AIMT) Completes And Exceeds North American Enrollment Target Ahead Of Schedule In Phase 3 PALISADE Trial Of AR101 For The Treatment Of Peanut Allergy; Company Accelerates Plans For Real-World Experience Study In The U.S. 9/21/2016
The Drugmaker That Could Knock Gilead (GILD) Off Its HIV Throne 9/20/2016
How Ionis Pharma (IONS) is Beating the Pants Off of Competitors Like Alnylam (ALNY), Arrowhead Pharma (ARWR) and Moderna 9/20/2016
Will Biogen (BIIB)’s Alzheimer’s Drug Be a Miracle Drug or Just Another Bomb? 9/20/2016
Another Good Day for Amgen (AMGN) as Repatha Phase III GLAGOV Trial Met Primary, Secondary Endpoints 9/20/2016
Biofrontera AG Completes Patient Recruitment Of Phase III Trial Of Ameluz In Combination With Daylight-PDT 9/20/2016
Amgen (AMGN), UCB Group (UCBJF.PK)'s Romosozumab Showed Significant Results in Phase III Study 9/19/2016
Novavax (NVAX) Stayin' Alive After Shares Crater on Flunked Phase III 9/19/2016
CoLucid Pharma (CLCD) Provides Interim Update On GLADIATOR 9/19/2016
FDA Takes Back Special Protocol Assessment for Active Biotech (BTPC)'s Laquinimod 9/19/2016
Radius Health (RDUS) Announces Publication Of Additional Positive Results From The Phase 3 ACTIVE Trial Of Abaloparatide-SC In JBMR 9/19/2016
Pfizer (PFE) Announces Positive Top-Line Results From REFLECTIONS B537-02 Study For PF-06438179 (Infliximab-Pfizer) A Potential Biosimilar To Remicade (Infliximab) 9/19/2016
CoLucid Pharma (CLCD) Announces Achievement Of Secondary Endpoints In SAMURAI 9/19/2016
Novartis AG (NVS) Drug For Multiple Sclerosis Shows Reduction In Risks 9/19/2016
Diffusion Pharma Successfully Completes Animal Toxicity Studies In Preparation For Phase III Pivotal Trial Of TSC In New Diagnosed Glioblastoma Patients 9/19/2016
SELLAS Life Sciences Group Receives FDA Fast Track Designation Of Galinpepimut-S For The Treatment Of Malignant Pleural Mesothelioma 9/19/2016
Quark Pharmaceuticals Inc. Chief Scientist Provides An Overview Of The Company's Clinical And Nonclinical Pipelines 9/19/2016
Gilead (GILD) to Release Data on 9 Clinical Trials Before End of the Year 9/16/2016
Takeda Pharmaceutical Co. Ltd. (TKPYY) Release: Favorable Benefit: Risk Profile For Vedolizumab As Induction And Maintenance Therapy In TNF-Naïve Or TNF-Failure Patients With Moderately To Severely Active Ulcerative Colitis Published In Clinical Gastroenterology And Hepatology 9/16/2016
Novo Nordisk A/S (NVO)'s New Diabetes Med Semaglutide Slashes Heart Disease Risk 9/16/2016
Merck & Co. (MRK) Presents New Data Examining Durable Efficacy With Investigational Cladribine Tablets In Multiple Sclerosis 9/16/2016
AstraZeneca PLC (AZN) Release: Phase III Combination Trial Of BYDUREON And FARXIGA Shows Significant Blood Sugar Reduction In Patients With Type 2 Diabetes 9/16/2016
Pfizer (PFE) Receives Positive CHMP Opinion For IBRANCE (Palbociclib) In Combination With Endocrine Therapy For The Treatment Of HR+/HER2- Metastatic Breast Cancer In Europe 9/16/2016
Treatment Effects Maintained Over Six Years In Patients With Relapsing Remitting Multiple Sclerosis Who Received Sanofi Genzyme (SNY)’s Lemtrada (Alemtuzumab) In Clinical Trials 9/16/2016
OptiNose AS Presents Data From Phase III Trials With Investigational Product Using Exhalation Delivery System Technology For Treatment In Patients With Chronic Rhinosinusitis (CRS) With And Without Nasal Polyps 9/16/2016
SoCal's Aerie (AERI) Stock Soars Over the Rainbow on Positive Phase III Eye Drug Data 9/16/2016
CHMP Recommends Approval Of Eli Lilly (LLY)'s Olaratumab, In Combination With Doxorubicin, For Advanced Soft Tissue Sarcoma 9/16/2016
Amgen (AMGN) Receives Positive CHMP Opinion For Parsabiv (Etelcalcetide) For The Treatment Of Secondary Hyperparathyroidism In Adult Patients With Chronic Kidney Disease On Hemodialysis 9/16/2016
Acasti Pharma Reports Positive CaPre Omega-3 Bridging Study Data 9/15/2016
AcelRx (ACRX) Surges as Pain Drug is Found Safe in Final Late-Stage Study 9/15/2016
Merck & Co. (MRK), Pfizer (PFE)'s Diabetes Candidate Meets Late-Stage Study Goals 9/15/2016
GlaxoSmithKline (GSK)'s Experimental Shingles Vaccine 90% Effective in People Over Age 70 9/15/2016
Results From 1,000-Patient, Global Real-World Patient-Reported Outcomes Study Of Sanofi Genzyme (SNY)’s Aubagio (Teriflunomide) In Patients With Relapsing Multiple Sclerosis Demonstrate High Levels Of Treatment Satisfaction 9/15/2016
AbbVie (ABBV) And Biogen (BIIB) Release: New Data Presented At ECTRIMS Reinforce Efficacy Of ZINBRYTA (Daclizumab) And Support Long-Term Safety Profile 9/15/2016
Otonomy (OTIC) Successfully Completes Open-Label Clinical Trial For OTIPRIO In Patients With History Of Otitis Media Requiring Tympanostomy Tubes 9/15/2016
Innovent Biologics Starts China Trials of Two Biologic Drug Candidates 9/15/2016
Intarcia Completes First Close Of A Major Equity Financing; Poised For ITCA 650 NDA Filing For Type 2 Diabetes, Commercial Readiness And Pipeline Progression 9/15/2016
Eisai Inc. (ESALF.PK) Announces New FYCOMPA (Perampanel) Data Presented At The 12th European Congress On Epileptology (ECE) 9/14/2016
Biogen (BIIB) Shows Off New Tecfidera Data in MS Trials 9/14/2016
Genentech (RHHBY) Release: Phase III Efficacy Results Of Investigational Medicine OCREVUS (Ocrelizumab) Reinforced By Exploratory Analyses In Two Forms Of Multiple Sclerosis 9/14/2016
Will FDA’s Scrutiny of Pfizer (PFE)’s Chantix Trial Go Up in Smoke? 9/13/2016
10 Biotechs—Count ‘Em, 10!—With Big Decisions in the Fourth Quarter 9/13/2016
Citius Pharma Initiates Mino-Lok Phase 3 Trial 9/13/2016
Can-Fite BioPharma (CFBI) Receives Notice Of Allowance For Psoriasis Patent In Europe Ahead Of Phase III Trial 9/13/2016
Portola (PTLA) Announces Upcoming Data Presentations On Andexxa (Andexanet Alfa) At Neurocritical Care Society 2016 Annual Meeting 9/13/2016
Adamas Pharma (ADMS) Announces Two Data Presentations On ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) At The 4th World Parkinson Congress 9/13/2016
Lexicon Pharma (LXRX) Rockets on Late-Stage Diabetes Drug Data 9/12/2016
Long-term Analysis Of All 695 Patients Enrolled In NovoCure’s Phase 3 Pivotal Trial In Newly Diagnosed Glioblastoma Confirms Superior Progression Free And Overall Survival Seen In The Trial’s Interim Analysis 9/12/2016
Angionetics' Generx [Ad5fgf-4] Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery Disease 9/12/2016
Tesaro (TSRO) Receives FDA Fast Track Designation For Niraparib And Initiates Rolling NDA Submission 9/12/2016
Cytokinetics (CYTK) Announces Additional Results From COSMIC-HF To Be Presented At The HFSA Annual Scientific Meeting 9/12/2016
Collegium (COLL) Release: Review Of Xtampza ER Published In JAMA 9/9/2016
Investors Sigh With Relief as bluebird bio (BLUE) Improves Its Gene Therapy Process 9/9/2016
Auris Med (EARS) Achieves Midpoint For Enrollment In Phase 3 Trial Of AM-111 In Sudden Deafness 9/9/2016
Theravance Biopharma (TBPH) Touts Significant Data from Pivotal Phase III FULFIL Study 9/8/2016
Boehringer Ingelheim Release: New Analysis Showed Dose Adjustment Of Gilotrif (Afatinib) Improved Tolerability Without An Apparent Impact On Efficacy In Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer 9/8/2016
Boehringer Ingelheim Release: New Analysis Showed Dose Adjustment Of Giotrif (Afatinib) Improved Tolerability Without An Apparent Impact On Efficacy In Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer 9/8/2016
GenSight Biologics Receives Approval To Include Teenage Patients In RESCUE And REVERSE Phase III Trials With GS010 In Leber’s Hereditary Optic Neuropathy 9/8/2016
Cambridge's CoLucid Pharma (CLCD) Rockets on Late-Stage Migraine Data 9/7/2016
Shionogi Release: Naldemedine Phase III Study Demonstrates Long-Term Safety And Efficacy For The Treatment Of Opioid-Induced Constipation 9/7/2016
Exelixis (EXEL) Announces Outcome From First Planned Interim Analysis Of The Phase III CELESTIAL Trial Of Cabozantinib In Patients With Advanced Hepatocellular Carcinoma 9/7/2016
Takeda (TKPYY) Initiates Global Phase III Clinical Trial (TIDES) Of Dengue Vaccine Candidate (TAK-003) 9/7/2016
vTv Therapeutics (VTVT) Completes Enrollment Of Part A Of Pivotal Phase III Trial Evaluating Azeliragon For The Treatment Of Patients With Mild Alzheimer’s Disease 9/7/2016
Cincinnati Children's Hospital Medical Center Release: Drug Reduces Seizure Frequency In Children With Tuberous Sclerosis Complex 9/7/2016
Boehringer Ingelheim Relelase: New Long-Term Data Demonstrates Continued Safety And Beneficial Effect Of Ofev (Nintedanib) For Patients With IPF 9/7/2016
September is a Busy Month for 7 Biotechs 9/6/2016
AstraZeneca PLC (AZN)'s Asthma Candidate Does Well in Final Late-Stage Test 9/6/2016
Boehringer Ingelheim Release: New Data: STIOLTO RESPIMAT (Tiotropium Bromide+Olodaterol) Inhalation Spray Significantly Improved Exercise Capacity In People With COPD 9/6/2016
Boehringer Ingelheim Release: New Data: Spiolto Respimat Significantly Improves Exercise Capacity In People With COPD 9/6/2016
Versartis (VSAR) Presents Efficacy, Safety, Metabolic And Adherence Data For Somavaratan In Oral Session At The International Congress Of Endocrinology 9/6/2016
Boehringer Ingelheim Release: Tiotropium Respimat Improved Lung Function In Children With Asthma Aged 6-17 And Is Well-Tolerated Compared To Placebo In Children Aged 1-171-5 9/6/2016
Tonix Pharma (TNXP) to Stop Testing Lead Pain Drug, Stock Craters 9/6/2016
GlaxoSmithKline (GSK) Presents Positive Results From Phase III Fulfil Study Of Closed Triple Combination Therapy Ff/Umec/Vi Versus Symbicort Turbohaler In COPD At ERS International Congress 9/6/2016
vasopharm BIOTECH GmbH Announces Enrollment Of First Patient In Phase III Traumatic Brain Injury (TBI) Trial 9/6/2016
Aquinox (AQXP) Initiates Patient Dosing In LEADERSHIP 301 Phase III Clinical Trial Of AQX-1125 In Interstitial Cystitis/Bladder Pain Syndrome 9/6/2016
MorphoSys AG Initiates Phase 2/3 Trial Of CD19 Antibody MOR208 Plus Bendamustine In Patients With Relapsed Or Refractory DLBCL 9/6/2016
Faron Pharmaceuticals Ltd. Release: Interim Results 2016: Progress Continued In Traumakine Phase III And With Clevegen Indications Extended 9/6/2016
Merck & Co. (MRK) Terminates Development of Osteoporosis Drug Due to Stroke Risk 9/2/2016
Genentech (RHHBY)'s Tecentriq Shows Positive Data in Phase III Trial, Has an Upcoming Action Date in October 9/2/2016
Why Cytokinetics (CYTK) Stock Dropped on the Good News of an Upcoming Phase III Trial 9/2/2016
CEL-SCI (CVM) Reports Monthly Patient Enrollment In August For Its Phase III Head And Neck Cancer Trial 9/2/2016
3 Biotechs Expecting to Release Clinical Trial Data Soon 9/1/2016
Array BioPharma (ARRY) Announces FDA Acceptance Of Binimetinib NDA For Patients With Advanced NRAS-Mutant Melanoma 9/1/2016
Cytokinetics (CYTK) And Amgen (AMGN) To Advance Omecamtiv Mecarbil To Phase III Clinical Development 9/1/2016
Achaogen (AKAO) Completes Patient Enrollment In Phase 3 EPIC Clinical Trial Of Plazomicin 9/1/2016
Amgen (AMGN) And Servier Extend Omecamtiv Mecarbil Collaboration In Chronic Heart Failure 9/1/2016
Investors Elated as Relypsa (RLYP)'s Phase IV Study of Veltassa Successful 8/31/2016
Rigel (RIGL)'s Bleeding Disorder Drug Passes First of Two Key Late-Stage Trials 8/30/2016
Vectura (VEC.L)'s Asthma Med Flutiform Flunks Final Late-Stage Study 8/30/2016
Marathon Pharma Announces Neurology Publication Of Pivotal Phase III Data For Deflazacort For Duchenne Muscular Dystrophy 8/30/2016
Portola (PTLA) Announces Interim Results From Ongoing Phase IIIb/IV ANNEXXA-4 Study Of Factor Xa Inhibitor Antidote Andexxa (Andexanet Alfa) In Patients With Acute Major Bleeding 8/30/2016
SAGE Therapeutics (SAGE) And Collaborators Announce Publication Highlighting Epidemiology And Burden Of Illness For Super-Refractory Status Epilepticus In Journal Of Medical Economics 8/30/2016
SIGA (SIGA) Announces Completion Of Enrollment And Dosing In The Final Cohort Of Phase III Study Of TPOXX (Tecovirimat) 8/30/2016
Regeneron (REGN), Sanofi (SNY)'s Potential Blockbuster Praluent Passes Late-Stage Test 8/30/2016
Amgen (AMGN) Announces Positive Top-Line Results From Phase 3 Study Of Prolia (Denosumab) In Patients Receiving Glucocorticoid Therapy 8/29/2016
AcelRx (ACRX) Presents Results From Phase 3 Study Of ARX-04 In The Emergency Department At The International Society For Burn Injuries 8/29/2016
CTI BioPharma's Pacritinib Shows Mixed Results in Phase III Test; Full Clinical Hold Still In Effect 8/29/2016
Nymox (NYMX)'s New Phase III Long-Term U.S. Results For Prostate Enlargement Drug Fexapotide Show 8/29/2016
Taking a Closer Look at Nymox (NYMX)'s 'Overinflated' Prostate Drug Hype 8/29/2016
Adocia's Foot Ulcer Med Flunks Phase III Test 8/26/2016
Novartis AG (NVS) Touts Phase III Data for MS Drug Siponimod 8/25/2016
Sunesis (SNSS) Announces Publication in "Drugs" Detailing Molecular And Pharmacologic Properties Of Vosaroxin 8/25/2016
NeuroDerm (NDRM) Initiates Patient Enrollment In A Phase III Trial Of ND0612L For The Treatment Of Parkinson’s Disease 8/25/2016
INSYS Reports Phase III Trial Of Sublingual Buprenorphine Spray Met Primary Endpoint In Patients With Moderate-To-Severe Postoperative Pain After Bunionectomy 8/24/2016
Nymox Pharmaceutical (NYMX) Reports Successful New Long-Term Fexapotide Placebo Crossover Study Results: Major Reduction In Incidence Of Surgery 8/24/2016
RegeneRx Biopharmaceuticals, Inc. (RGRX) Joint Venture To Begin Second Phase 3 Study Of RGN-259 For Dry Eye Syndrome In 3rd Quarter 8/24/2016
Inotek (ITEK) Announces The Completion Of The Recruitment Phase Of MATrX-1, The First Phase 3 Clinical Trial Of Trabodenoson For Glaucoma 8/24/2016
DalCor Announces Opening Of International Trial Sites For Its Dal-Gene Phase 3 Cardiovascular Outcomes Trial 8/23/2016
Galapagos (GLPG.BR) Release: Finch Filgotinib Phase 3 Program Initiated In Rheumatoid Arthritis 8/23/2016
Eli Lilly (LLY)'s Incoming CEO May Carry First Alzheimer's Drug Across The Finish Line 8/22/2016
Eli Lilly (LLY) And AstraZeneca PLC (AZN) Receive FDA Fast Track Designation For AZD3293, An Investigational Treatment For Early Alzheimer's Disease 8/22/2016
Mezzion (140410.KQ) And NHLBI Initiate Enrollment In A Pivotal Phase 3 Clinical Trial Of Udenafil In Adolescents With Fontan Surgical Palliation - An Orphan Drug Indication 8/22/2016
A Look at Amgen (AMGN)'s Pipeline: Will it Help the Company Grow? 8/19/2016
Auris Med (EARS)'s Tinnitus Drug Misses Main Goals in Study; Shares Sink 8/18/2016
Intercept Pharma (ICPT) Release: The New England Journal of Medicine Publishes Results Of Phase III POISE Trial Of Ocaliva (Obeticholic Acid) For The Treatment Of PBC 8/18/2016
Remedy Pharmaceuticals, Inc.’ Edema And Neuro-Inflammation Advisory Board Provides Guidance On Opportunities In CNS Conditions 8/18/2016
ARCA biopharma Announces 100th Patient Randomized Into The GENETIC-AF Phase 2B/3 Clinical Trial 8/18/2016
Vertex (VRTX) Dumps Phase III Cystic Fibrosis Study 8/17/2016
Indivior Shows Off Late-Stage Opiod Addiction Trial Data 8/17/2016
Cytokinetics (CYTK) Completes Enrollment In VITALITY-ALS, Phase III Clinical Trial Of Tirasemtiv In Patients With ALS 8/17/2016
OncoGenex (OGXI) Hires Advisor, Seeks Strategic Alternatives After Cancer Drug Custirsen Study Fails 8/16/2016
Radius Health (RDUS) Release: JAMA Publishes Positive Phase 3 Data For Abaloparatide In Postmenopausal Women With Osteoporosis 8/16/2016
Primary Endpoint Met in pSivida (PSDV)’s First Medidur Phase III 8/16/2016
ViiV Healthcare Launches Phase III Programme Evaluating A Two-Drug Regimen Combining Dolutegravir And Lamivudine For HIV-1 Treatment 8/16/2016
Ascendis Pharma A/S Announces R&D Update To Review Expanded Pipeline And Long-Term Strategic Outlook 8/16/2016
Axovant (AXON) Announces Expansion Of Dementia Pipeline And Reports Financial Results For The First Fiscal Quarter Ended June 30, 2016 8/16/2016
AcelRx (ACRX)' ARX-04 Phase 3 Trial Met its Primary Endpoint 8/15/2016
BeyondSpring Pharmaceuticals Announces First Patient Enrolled In China In A Global Phase 3 Trial Of Plinabulin For Non-Small Cell Lung Cancer 8/15/2016
Paratek Pharmaceuticals, Inc. Initiates Phase 3 Study Of Oral-Only Omadacycline In ABSSSI 8/15/2016
Ritter Pharmaceuticals, Inc. Completes Enrollment For Phase 2b/3 Trial Of RP-G28 In Lactose Intolerance 8/15/2016
Acacia Pharma Announces Positive Results From A Pivotal Phase 3 Trial Of BAREMSIS For The Treatment Of Post-Operative Nausea & Vomiting 8/12/2016
Spark Therapeutics (ONCE) Touts Long-Term Positive Phase III Gene Therapy Data 8/11/2016
Resverlogix (RVX.TO) Announces Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study Of Apabetalone (RVX-208) 8/11/2016
Ascendis Pharma A/S Initiates Phase 3 Registration Trial For TransCon Growth Hormone In Children With Growth Hormone Deficiency 8/11/2016
PharmaMar Announces The IDMC´s Response On The CORAIL Trial Using PM1183 8/11/2016
Nymox Pharmaceutical (NYMX) Announces Prostate Drug Progress 8/11/2016
ProMetic Life Sci (PFSCF.PK) Completes Patients' Enrolment In Pivotal Plasminogen Phase 2/3 Clinical Trial 8/11/2016
Eli Lilly (LLY)'s Breast Cancer Drug Failed to Meet Phase III Goals, But Panel Recommends Continuation of Trial 8/10/2016
AstraZeneca PLC (AZN)'s Lung Cancer Drug Flunks Late-Stage Test 8/10/2016
Eisai Company (ESALY.PK) Release: U.S. FDA Confirms Sufficient Data To Advance Investigational Bace Inhibitor E2609 For Treatment Of Early Alzheimer’s Disease To PHASE III 8/10/2016
AstraZeneca PLC (AZN) Announces Positive Top-Line Data From Two Phase III SYMBICORT Studies 8/10/2016
Moberg Pharma AB (Formerly known as Moberg Derma) Announces Approvals To Start Phase 3 Study For MOB-015 In U.S. And Canada 8/10/2016
Results From Merck & Co. (MRK)’s Phase 3 Study Evaluating ZEPATIER (Elbasvir And Grazoprevir) In Patients With Chronic Hepatitis C Receiving Treatment For Opioid Dependence Published In Annals Of Internal Medicine 8/9/2016
ProMetic Life Sci (PFSCF.PK) Completes Adult Patients' Enrolment In Pivotal IVIG Phase 3 Clinical Trial 8/9/2016
SIGA (SIGA) Announces Data Safety Monitoring Board (DSMB) Approval To Complete Subject Enrollment In The Final Cohort Of Phase III Study Of TPOXX (Tecovirimat) 8/9/2016
Akebia (AKBA) Initiates INNO2VATE Phase 3 Program For Vadadustat In Dialysis Patients With Anemia Related To Chronic Kidney Disease 8/9/2016
ThromboGenics NV (TBGNF) 2-Year OASIS Study Results Published In Ophthalmology, Journal Of The American Academy Of Ophthalmology (AAO) 8/8/2016
Pfizer (PFE) Announces Publication Of New Analysis Showing Long-Term Therapy With VYNDAQEL (Tafamidis) Slowed Progression Of Rare Neurodegenerative Disease 8/8/2016
Alnylam (ALNY) Completes Enrollment In ENDEAVOUR Phase III Study With Revusiran, An Investigational Rnai Therapeutic For Patients With Hereditary ATTR Amyloidosis With Cardiomyopathy (Hattr-CM) 8/8/2016
Bristol-Myers Squibb (BMY)'s Failed Lung Cancer Data Sends Stock Plunging 8/5/2016
Sarepta (SRPT) Stock Surges After Government Website Indicates Firm is Recruiting for Phase III Study 8/5/2016
Allergan (AGN), Gedeon Richter (RIG2.F) Face Setback in Cariprazine Antidepressant Trial 8/5/2016
Amarin (AMRN) And FDA Reaffirm Concurrence On REDUCE-IT Through Special Protocol Assessment Agreement Amendment 8/4/2016
Anthera Pharma (ANTH)Announces Completion Of Dosing In CHABLIS-SC1 Phase III Clinical Study With Blisibimod 8/4/2016
Palatin Tech (PTN) Announces Completion of All Patient Visits In Phase 3 Clinical Trials of Bremelanotide for Hypoactive Sexual Desire Disorder 8/4/2016
Lexicon Pharma (LXRX) Provides Clinical Pipeline Update And Reports 2016 Second Quarter Financial Results 8/4/2016
FDA Bestows Novartis AG (NVS)'s Breast Cancer Pill With Breakthrough Tag 8/3/2016
ViroMed Approved To Start Trial Of Gene Therapy For Ischemic Heart Disease 8/3/2016
Mast Therapeutics (MSTX) Announces Issuance Of Composition Of Matter Patent Covering Vepoloxamer 8/3/2016
PharmaMar S.A. Initiates A Pivotal Phase III ATLANTIS Study With PM1183 In Combination With Doxorubicin In Patients With Small Cell Lung Cancer 8/2/2016
Takeda (TKPYY) And TiGenix Announce Publication In The Lancet Of 24-Week Results Of The Phase 3 ADMIRE-CD Trial Investigating Cx601 In The Treatment Of Complex Perianal Fistulas In Patients With Crohn's Disease 8/2/2016
Takeda (TKPYY), Seattle Genetics (SGEN) Show Off Significant Phase III ALCANZA Data for T-Cell Lymphoma 8/1/2016
Biogen (BIIB) Pays Ionis Pharma (IONS) $75 Million for Successful Late-Stage Nusinersen Data 8/1/2016
MEI Pharma (MSHL)'s Pracinostat Called a Breakthrough By the FDA 8/1/2016
Eisai Company (ESALY.PK) Presents Results Of Additional Analysis Of Phase III Study Of Anticancer Agent Halaven At 14th JSMO Annual Meeting Plenary Session 8/1/2016
Sanofi (SNY) And Regeneron (REGN) Announce EMA Acceptance For Review Of Marketing Authorisation Application For Sarilumab 8/1/2016
Otonomy (OTIC) Successfully Completes One-Year, Multiple-Dose Clinical Safety Trial For OTO-104 In Ménière’s Disease Patients 8/1/2016
CEL-SCI (CVM) Reports Monthly Patient Enrollment In July For Its Phase III Head And Neck Cancer Trial 8/1/2016
AcelRx (ACRX) To Present Initial Results Of Phase 3 Study Of ARX-04 At World Congress Of Mountain & Wilderness Medicine 8/1/2016
More Positive Phase III Data for Pfizer (PFE)'s Xeljanz in Ulcerative Colitis 7/29/2016
First Patient Enrolled In Mallinckrodt (MNK) Phase 3 Terlipressin Trial 7/29/2016
AbbVie (ABBV) Announces Initiation Of Phase 3 Study Of Venetoclax In Patients With Relapsed Or Refractory Multiple Myeloma 7/29/2016
Edge Therapeutics Announces First Patient Treated In Phase III NEWTON 2 Study Of EG-1962 In Adult Patients With Aneurysmal Subarachnoid Hemorrhage 7/29/2016
Quark Pharmaceuticals Inc. Awarded Key Patent For QPI-1007 Ocular Neuroprotectant 7/29/2016
AcelRx (ACRX) Provides Corporate Update And Reports Second Quarter And Six Months 2016 Financial Results 7/29/2016
AstraZeneca PLC (AZN) Kills Six Pipeline Programs 7/28/2016
Omeros (OMER) Confirms OMS721 Phase 3 Development Plan With EMA 7/28/2016
Biofrontera AG Receives Favourable CHMP Assessment For Field-Directed Therapy And Files BCC Application 7/28/2016
Amgen (AMGN) Reports Second Quarter 2016 Financial Results 7/28/2016
Nektar Therapeutics (NKTR) To Announce Financial Results For The Second Quarter 2016 On Wednesday, August 3, 2016, After Close Of U.S.-Based Financial Markets 7/28/2016
TauRx Pharma's Much-Watched Alzheimer's Drug Flops in Trial 7/27/2016
Boehringer Ingelheim Halts Two Phase III Trials for Lung Cancer Drug Gilotrif 7/27/2016
CSL Behring Presents Pivotal Efficacy Data For AFSTYLA In Adolescents And Children With Hemophilia A At The World Federation Of Hemophilia 2016 World Congress 7/27/2016